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Abstract:   249 words  
 
Objective: To assess prevalence of, and factors associated with tobacco smoking and 
dependence in HIV patients. 
Design: A one-day cross-sectional national survey.  
Methods: 727 consecutive outpatients from a representative sample of 82 French units 
specialized in HIV-infected patient care were asked to complete a self-administered 
questionnaire, assessing smoking habits, dependence, cessation motivation, other substance 
abuse, socio-cultural characteristics, life with HIV and its treatment.  Smoking prevalence and 
dependence were assessed and compared with a representative sample of the general French 
population; associated factors were determined. 
Results: 593 (82%) patients completed the questionnaire, 12% were active or ex-intravenous 
drug users, 37% were homosexual men; 43% were active smokers (31% in the French 
population). Fifty-six percent of smokers were classified as moderately or highly dependent, 
14% of smokers were highly motivated and free of other substance abuse and of depressive 
symptoms. Smoking was independently associated with male sex (OR=2.38; 95% CI: 0.99-
1.11), BMI (OR=1.08; 95% CI: 1.14-1.03), smoking environment (OR=4.75; 95% CI: 3.02-
7.49), excessive alcohol consumption (OR=2.50; 95% CI: 1.20-5.23), illicit drug use 
(OR=2.43; 95% CI: 1.41-4.19), HIV status disclosure to family (OR=1.81; 95% CI: 1.16-
2.85) and experience of rejection due to disclosure (OR=1.90; 95% CI: 1.14-3.17). Disclosure 
and drug substitutes’ usage were associated with high tobacco dependence. 
Conclusions: Tobacco smoking is frequent and associated with other substance use and HIV 
disclosure. The rate of smokers who would be good candidates for a standard tobacco 
cessation program appears very low. Tobacco reduction or cessation strategies should be 
adapted to this population. 
 
Keywords: Tobacco, HIV, dependence, motivation, associated factors 
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INTRODUCTION   
Cardiovascular diseases and lung cancer are becoming competing causes of death in 
people living with HIV and AIDS on antiretroviral treatment [1, 2]. Recent evidence suggests 
that the prevalence of cigarette smoking among HIV-infected patients is elevated compared to 
the general population, smoking being a well-established risk factor for several diseases 
including pulmonary infectious diseases, lung cancer and cardiovascular diseases [2-7]. 
Prognosis of lung cancer is dramatically worse in the HIV-infected population as compared to 
the non-infected population [8, 9]. In the case of cardiovascular diseases, smoking’s negative 
effects add to the risks already posed by increased lipid level, increased insulin resistance and 
diabetes which are frequent in patients receiving antiretroviral treatments [10]. Given the 
association between smoking and adverse health outcomes, smoking cessation programs are 
clearly needed in HIV-infected patients [6]. 
However, the reasons for higher cigarette smoking prevalence in the HIV-infected 
patient population are unclear. Smoking characteristics in the HIV-infected population 
probably differ from those in the general population due to the constraints related to a chronic 
life-threatening disease and its therapy, related psychological and behavioural factors and, in 
some patients, other substance abuse. All these aspects probably likely impact smoking 
prevalence, the degree of tobacco dependence, motivation to stop smoking and smoking 
cessation strategies success rates.  
To understand the basic mechanisms that regulate smoking and cessation in smokers 
living with HIV, we conducted a one-day national survey on tobacco use in a large 
representative population of HIV-infected outpatients to examine the relationship between 
tobacco use characteristics, cessation plans, and patient characteristics. 
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METHODS  
Patients and Study Design 
The survey was conducted on May 30th 2006 in a representative sample of French 
units specialized in the care of HIV-infected patients. One hundred and sixty-eight units were 
randomly chosen among all French units having declared at least 5 diagnosed cases of HIV 
each year during the 2000-2004 period (the declaration of diagnosed cases of HIV to the 
health ministry is mandatory in France). Among the 168 solicited units throughout France, 80 
agreed to participate in the study.  
All patients coming for their regular follow-up visit or for a day hospitalisation were 
asked to participate in this survey. Written informed consent was obtained for all patients. The 
local ethics committee of Paris Hôtel-Dieu approved the study.  
 
Data Collected  
We collected the following data for each patient through a practitioner (provider ??) 
questionnaire (whether patients agreed to respond to the self-administered questionnaire or 
not): sex, age, geographic origin, risk factors for HIV infection, worst stage of disease in 
patient as described by Center for Disease Control and Prevention, CD4 cell count and HIV-
RNA level at the time of the consultation as well as the then current prescription of 
antiretroviral therapy. For patients who refused to participate in the study, additional 
questions answered by the practitioner provided the following information: smoking status, 
geographic origin, cardiovascular risk factors, and professional status (active worker, retired 
or unemployed). Patients who participated in the study filled out an anonymous self-
administered multiple-choice questionnaire, which asked for demographic data, socio-
economic status, HIV infection treatment and history, substance abuse, and symptoms of 
anxiety and depression. Self-reported symptoms related to antiretroviral drugs were assessed 
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using two approaches. First, patients were asked if they had ever experienced an adverse drug 
reaction related to antiretroviral therapy. Secondly, information about self-reported symptoms 
was obtained using a 13-item scale. This scale corresponds to the French version of the 
symptom index, validated by Justice et al. [11]. This scale was previously adapted and used in 
a French cohort of patients treated by antiretroviral therapy [12]. Patients were asked if they 
had experienced at least one of the following symptoms during the previous 4 weeks: 
diarrhoea, nausea, stomach pain, headache, change in taste, itching skin, muscle pain, 
heartburn, sore mouth, vomiting, fever, kidney stones or fatigue. Patients were categorized as 
having a subjective perception of antiretroviral adverse events if they reported at least one 
symptom.  
 
Tobacco, alcohol, drugs and psychoactive substance use 
The following tobacco use characteristics were monitored: prevalence, contact with 
other smokers, tobacco dependence using the Fagerström Test for Nicotine Dependence (no 
or low dependence (< 5) versus moderate or strong dependence (≥5)) [13], motivation to stop 
smoking (using Q mat scale; high and intermediate motivation versus insufficient motivation) 
as well as use of other substances (alcohol, cocaine…), antidepressants or anti-anxiety 
medications in the previous six months [14]. Patients were asked if they have consumed 
rarely, frequently or every day one of any substances on a predefined list (Figure 1) during the 
preceding six months. Patients were classified as an active illicit drug user if they declared 
having consumed at least one illicit drug during the preceding six months. Reasons for 
smoking were also assessed. Alcohol consumption was categorized using the CAGE-DETA 
scale (0-4) [15]. Patients were considered to have excessive consumption if their total score 
was above 2. According to the World Health Organisation recommendations, regular tobacco 
smokers are defined as consumers of one or more cigarettes a day for at least one year [16]. 
Individuals were considered as former smokers if they had a history of regular smoking and 
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declared having quit smoking for at least 1 month and had not smoked any cigarettes during 
the month preceding the survey. In order to ensure confidentiality, each questionnaire was 
distributed in a sealed envelope identifiable only by a unique identification number for each 
patient. Pack years of smoking were determined based on the average daily amount of 
cigarettes reported by the patients over the entire time of use. For active smokers, the 
involvement of their health provider in providing tobacco education and cessation program 
referral was assessed. Patients’ perception of the risk of developing tobacco related health 
problems was assessed through a visual scale (0 (none) to 10 (high)). 
 
Anxiety, depression and experience of disclosure 
Anxiety and depression were assessed using the hospital anxiety and depression 
(HAD) scale which includes 14 questions (7 relating to anxiety and 7 to depression) 
concerning individuals’ experience over the previous week [17]. Patients were asked whether 
they had experienced rejection due to disclosure of HIV seropositive status. 
 
Comparison to the French HIV infected population and the general French population  
The main characteristics (sex, age, HIV risk factors, CD4 cell count) between the 
population of the study and the French database on HIV infection (using the DMI-2 software) 
which reports information on 43, 244 HIV-infected patients were compared to confirm the 
representativity of our studied population.  
Cigarette smoking prevalence, tobacco dependence using Fagerström scale, and 
alcohol consumption were compared to the 2005 French National health survey (Baromètre 
santé INPES; available at http://www.inpes.sante.fr/index.asp?page=Barometres/Baro2005 
_1R/ouvrage/presentation.asp) in the general population using a representative sample of 
28,221 individuals aged 18-75 years. 
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Statistical Analysis  
The quantitative variables were described as mean  standard deviations while 
qualitative variables were described as percentages.  
To assess comparisons between our sample and reference populations data (the French 
HIV-infected population and the general French population), we used the one-sample t test 
when comparing quantitative variables and the one-way chi-square test when comparing 
qualitative variables.  
Factors associated with each of the 3 following outcomes were investigated in our 
HIV population: smoking status (current/former/non), tobacco dependence (yes/no) and high 
smoking cessation motivation (yes/no). For each of these outcomes, a bivariate and a 
multivariate analysis were performed. In bivariate analysis, a one-way ANOVA was used to 
compare quantitative variables. The chi-square test was used to compare categorical variables. 
Variables that were related to outcomes in bivariate analysis (p<0.20) were kept in the 
multivariate analysis. Multivariate analysis of associated factors was performed using a 
polytomous nominal logistic regression or standard logistic regression, when appropriate. 
Based on an a priori significance level of 0.05, stepwise logistic regression (mixed methods) 
was performed was used to select the significant terms of the model. Odds ratios with 95% 
confidence interval (CI) were estimated. All statistical analyses were performed with SAS 
software, version 9.1 (SAS institute).  
A hierarchical cluster analysis (Ward method with a square Euclidean distance 
measure) was used to identify clusters of correlated variables among alcohol and drugs. All 
the variables included in the cluster analysis are binary, so that each of them contributes 
equally to the formation of clusters. A tree diagram illustrating the hierarchical relationships 
among variables was generated. 
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RESULTS 
Studied population  
Out of the 727 patients who were requested to fill in the questionnaire, 125 declined to 
participate. Of those who accepted, 593 (82%) responded clearly to the question on smoking 
status while 9 did not respond to the question on smoking status. Among the 125 patients who 
refused, 75 were male (22 homosexual and 53 heterosexual). Based on the provider completed 
survey, there was no difference in epidemiological data, CD4 cell count, plasmatic HIV-RNA 
value, CDC stage or percentage of HAART-receiving patients and rate of active smokers 
between the 593 patients who accepted and others (n=134). Among the 134, unemployed 
individuals were more frequent (22% vs 15%, p=0.0495), as were patients who had acquired 
HIV through IV drug addiction (23% vs 12%, p<0.0001). 
 
Comparison to the general French HIV-infected population 
As compared to the French Hospital Database on HIV, the present study population 
included older patients (mean age 45.19.8 versus 42.110.0, p<0.0001) and less frequently, 
patients who acquired HIV through IV drug addiction (12% vs 15%; p=0.0758). Mean CD4 
cell count (479.0265.7 vs 466.7274.4, p=0.2656), sex ratio (M/F) (2.3 versus 2.3, 
p=0.7456) and percentage of patients with CDC stage C HIV disease (25% vs 24%, 
p=0.3164) were not statistically different between the two populations. 
 
Characteristics of the studied population and tobacco use 
Among the 593 patients who participated in the study, 70% (415) were men; patients 
infected through intravenous drug use accounted for 12% (71/593), 37% (219/593) were men 
who had sex with men, 25% (148/593) of the patients were at CDC stage C, 80% (474/593) of 
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the patients were receiving antiretrovirals, and 57% (338/593) had undetectable viral load. 
Thirty-nine percent of patients had at least one cardiovascular risk factor (other than tobacco).  
Forty-three (255/593) percent of patients reported that they were active smokers, 17% 
(100/593) being former smokers and 40% (237/593) never having smoked, 53% (314/593) of 
patients declared being in a smoking environment. The rate of smoking was highly variable 
according to sex, age strata, geographic origin and HIV risk factors (Table 1). Mean age of 
regular tobacco consumption was 18 years old; mean cumulative consumption was 25  4 
pack-years. Among smokers, 52% reported having been questioned about tobacco by their 
practitioner, and only 10% were referred to smoking cessation program.  
Figure 1 shows the rate of patients with illicit consumption whether they were active 
smokers or not. Forty-one percent of patients reported taking tranquilisers, 20% taking 
antidepressants, 15% having excessive alcohol consumption (CAGE-DETA), 38% having at 
least one illicit consumption in the previous 6 months, 25% reported having taken cannabis 
during the previous 6 months.  
Among smokers, 38% reported having experienced rejection due to disclosure of HIV 
status as compared to 20% both in former-smokers and in non-smokers (p<0.0001) (Table 2). 
 
Factors associated with active smoking and with former smoking status 
Cluster analysis identified 5 groups of illicit consumptions: Tobacco, cannabis, 
poppers, alcohol and others (including ectasy, cocain, heroin, rohypnol, amphetamines, LSD, 
morphin or substitute drugs). Cannabis was the group most closely related to tobacco 
consumption (Figure 1). As cannabis consumption was co-linear with tobacco consumption, 
we did not include this variable in the multivariate analysis. Characteristics (other than 
cannabis consumption) associated with active smoking in bivariate analysis are shown in 
Table 2. Compared to non-smokers, multivariate analysis revealed active smoking to be 
associated with male sex, living with smoking environment, lower body mass index, 
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excessive alcohol consumption, illicit consumption, disclosure of HIV status to family, 
reported experience of disclosure rejection, and IV drug addiction as a HIV risk factor. (Table 
2).  
Factors associated with former smoking status as compared to non-smoking status 
were a smoking environment, IV drug addiction as a HIV risk factor and plans to practice a 
sport. 
 
Factors associated with tobacco dependence 
High and intermediate tobacco dependence assessed through the Fagerström scale was 
noted in 56% of patients. Table 3 shows variables associated with high and intermediate 
tobacco dependence in bivariate analyses. In multivariate analysis, disclosure of HIV status to 
family, and having taken substitution drugs or morphine during the 6 previous months were 
associated with intermediate and high tobacco dependence, whereas practicing sports was 
associated with lower dependence. 
 
Factors associated with high smoking cessation motivation 
Intermediate to very strong motivation to quit smoking was reported in 37% of 
patients. Motivation to quit smoking was independently associated with higher body surface 
area (OR=13.36, 95% CI =2.72-65.22), and with patients’ perception of the risk of developing 
tobacco related health problems (OR=1.24, 95% CI =1.09-1.41). Among smokers, the rate of 
patients who were highly motivated, had no other illicit drug use, and no depressive 
symptoms (total score on HAD depression subscale between 0 and 7) was 14%. 
 
Comparison to the French general population 
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The active smoking rate was significantly lower in the general French population than 
in the studied HIV-infected population (31% vs 43%)(p<0.0001). Intermediate and high 
tobacco dependence was 25% less frequent in the general French population as compared to 
the studied HIV-infected population (p<0.0001). Concerning other substance abuse, excessive 
alcohol consumption was reported by 14% of the smokers in the general French population as 
compared to 24% of the HIV-infected smokers (p<0.0001). Furthermore, 11% of the smokers 
in the general population declared cannabis consumption in the 6 previous months as 
compared to 50% of the HIV-infected smokers (p<0.0001).  
 
DISCUSSION 
Active smoking appears frequent in the HIV-infected population; however it is highly 
variable according to sex, HIV risk factors, and geographic origin. Smoking rate and 
characteristics are both associated with factors commonly found in the general population 
such as male sex or smoking environment, but also with factors specific to the HIV 
population such as disclosure of HIV status to family and reported experience of disclosure 
rejection. High rates of illicit substance use and tobacco dependence appear specific to this 
population. 
This study confirms the significantly higher prevalence of active tobacco smoking (43 
%) as compared to the French general population (31%). This rate is difficult to compare with 
the results reported in other studies of HIV-infected patients (50 to >70%), as the rate of 
active smokers among HIV-infected individuals appears to be highly variable according to 
sex, HIV-risk factors or geographic origin [4-6, 10, 18] and is thus dependent on the 
repartition of these characteristics in the studied population. For example, it ranges in our 
study from 9% in women originating from sub-Saharan Africa to 81% in patients who 
acquired HIV through IV drug addiction.  
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This high prevalence of tobacco consumption may be due to difficulties linked with an 
increased need for tobacco consumption or reduced motivation to stop tobacco consumption 
encountered by HIV-infected smokers. Several factors reported in our study could explain this 
situation. The HIV disease itself or its treatment, affecting the quality of life, may act as a 
predisposing factor. Of note is that the perception of antiretrovirals’ adverse effects was more 
frequently reported by active smokers as compared to non-smokers in bivariate analysis. 
Family and friends’ perception of HIV status may also have an impact. In fact, we found that 
disclosure of HIV status to family was associated with active smoking. This association is 
difficult to interpret; on the one hand, a behavioral factor may explain both the propensity to 
smoke and also to talk about HIV disease without any direct relationship between these 
behaviors; on the other hand, we can hypothesize that the stress induced by HIV status 
disclosure may exacerbate the tendency to smoke and/or to continue smoking. The 
identification of the perceived experience of rejection due to disclosure as independently 
associated with smoking status supports the hypothesis that the difficulties related to HIV 
status disclosure constitute a risk factor for tobacco consumption in this patient population. Of 
note is that HIV status disclosure was also independently associated with high dependence on 
tobacco.  
On the contrary, we did not find any differences in social status between smokers and 
non-smokers. In fact, precarious social conditions have been found to be associated with 
smoking status in HIV-infected patients [4]. This shows that smoking concerns the whole 
socio-economic spectrum. At the same time, the high rate of refusal to participate in this study 
among unemployed individuals may have had an impact on the results. 
In addition, the identification of smoking environment and IV drug addiction as HIV 
risk factors as being associated with both active smoker status and former smoker status 
suggests that these characteristics, while more frequent in active smokers, are not 
incompatible with quitting smoking. 
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The rates of illicit consumptions (alcohol, cannabis…etc.) and also of excessive 
alcohol consumption were considerably higher in the HIV-infected smokers (whether or not 
patients acquired HIV through IV drug addiction) as compared to the general population. 
Moreover, these two characteristics were independently associated with active smoking status 
whereas they were not with former smoking status. This argues for a global approach to 
substance abuse treatment in the HIV-infected smoking population.  
The rate of smokers moderately to highly dependent on tobacco according to the 
Fagerström scale was significantly higher in the HIV-infected population as compared to the 
general population. This level of dependency usually necessitates medical intervention to help 
quit smoking, which in the case of prescribing medication could interfere with antiretroviral 
treatments. This medical intervention is all the more essential in patients receiving substitutes 
for IV drugs, a characteristic associated with nicotine dependency in the smokers of this 
study.  
The rate of 37% of patients motivated to quit smoking seems comparable to those 
reported by others (20-40%) using other means to estimate motivation [6, 18, 19]. This 
motivation in the current study population appears to be related to the patients’ perception of 
the risk of developing tobacco- related health problems. Given the perception that death from 
AIDS is the inevitable outcome of a HIV infection diagnosis, many patients may have 
believed that quitting smoking was not going to improve their health. The health risks of 
smoking should be clearly communicated by the practitioner in charge of each patient. 
However, the rate of active smokers whose practitioner evoked tobacco consumption or who 
referred them to a tobacco specialist appears very low. The well-known “brief counseling 
method to quit smoking which consists of the 5 A’s”: Ask (about smoking), Advise (the 
patient to quit smoking), Assess (determine willingness to make a quit attempt), Assist (the 
patient to quit), Arrange (follow-up…) seems rarely used by physicians within this study 
[20].. Physicians in charge of HIV-infected patients should encourage smokers to consult 
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practitioners specialized in smoking cessation. Less than 15% of HIV-infected smokers in the 
present study had profiles suggesting a capacity to easily stop smoking: high motivation, no 
other illicit drug use, and no depressive symptoms, and to whom a standard tobacco cessation 
program could be proposed. In the large majority of cases, multidisciplinary intervention is 
needed using behavioral support, together with medication and the need to take into account 
depressive symptoms and anxiety in some. 
We acknowledge potential limitations to our study. First, the comparison of the 
characteristics of this study population with those of the population who refused to fill out the 
questionnaire shows that they were not comparable for all characteristics such as the 
proportions of IV drug addiction and of unemployed individuals, which were more frequent in 
the population of patients who refused to fill out the questionnaire. As the selected sample 
was randomly chosen among French hospitals, we assume that the studied population was as 
close to representative as possible of the whole population of HIV-infected outpatients 
monitored in France. We cannot exclude the possibility that the decision by certain French 
hospitals and certain HIV-infected patients to not participate in the study may have introduced 
a bias in the results. In fact, the characteristics of the HIV-infected patients of the present 
study (a younger population and fewer drug addicts) are not completely comparable to those 
of HIV patients monitored in French hospitals. 
Second, we only included outpatients and the studied population could thus be 
considered as not totally representative of HIV-infected individuals. However, our survey was 
conducted to evaluate the possibility of implementing a cessation program to specifically 
target outpatients. Finally, as we performed a cross-sectional study, it is neither possible to 
study the dynamic process of tobacco consumption nor to establish a causal relationship 
between tobacco consumption and the identified associated factors.  
In light of these results, it stands to reason that tobacco consumption has specific 
characteristics in the HIV-population and is closely related to life with HIV, and how the 
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patients’ circle of family and friends copes with his or her HIV status. Patients must be 
informed about the risk of continuing to smoke. Physicians must be aware of their central role 
in motivating this population of smokers to consider quitting. Efficacy of strategies combining 
cessation medication and a global behavioral approach should be assessed in this population 
using clinical trials. 
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Figure 1: Dendrogram showing the results of Ward's cluster analysis : hierarchical 
relationships among substance abuse in the study population. 
 
 Total 
population
N=593 
Smokers 
 
N=254 
 
Alcohol  15.3% 24.2% 
 
   
Ecstasy  3.6% 7.0% 
   
   
Cocain 6.8% 13.8% 
   
Heroin 2.2% 5.5% 
   
   
Rohypnol  1.0% 2.6% 
   
Amphetamines  0.2% 0.0% 
   
   
LSD      1.6% 3.1% 
   
Buprenorphine, 
or methadone, or 
morphin sulfate 
7.3%, 14.9% 
Poppers  17.3% 24.0% 
   
Cannabis  24.9% 50.3% 
   
   
Tobacco  43.0% 100% 
   
   
   
   
 
Note: Results are expressed by name of substance consumed, % of consumers among the 
study population (n=593), and among the smokers (n=254); LSD: lysergic acid 
diethylamide. The semi-partial R-square is an indicator of cluster isolation : high semi-
partial r-square values indicate a high level of cluster independence. 
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Table 1: Rate of active smoking according to demographic data and HIV risk factors in the 
593 HIV-infected patients who participated in the study. 
 
 
 
  Rate of active 
smokers (%) 
Total population  43 
Sex   
Male  48 
Female  31 
Age   
18-24  17 
25-34  41 
35-44  50 
45-54  45 
55-64  18 
65-75  10 
   
Geographic origin   
Europe  52 
North Africa  43 
Sub-Saharan Africa   25 
Other  19 
   
HIV risk factors   
 Homosexuality  49 
 IV drug addiction  82 
 Other  30 
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Table 2: Bivariate and multivariate analyses of factors associated with smoking, former smoking and non-smoking status in the 593 HIV-infected patients 
who participated in the study. 
 
 Bivariate analysis Multipartite analysis 
   Active smokers versus  
Non-smokers 
Former smokers  
versus non-smokers 
Variables Active 
smokers
N=254 
Former 
smokers 
N=103 
Non 
smokers 
N=236 
 
 
p 
  
 
OR 
 
 
95% CI 
 
 
p 
 
 
OR 
 
 
95% CI 
 
 
p 
            
Age (mean  SD; years)  43.17.6 47.110.0 46.111.3 0.0002  0.98 0.96-1.01 0.1124 1.02 0.99-1.05 0.1017 
Sex (%male) (female versus male) 79% 72% 60% <0.0001  2.38 1.43-4.00 0.0008 1.56 0.89-2.70 0.1187 
Body Mass Index (kg/m2) mean  SD 22.45.3 23.33.4 24.43.8 <0.0001  1.08 1.14-1.03 0.0007 1.05 0.99-1.11 0.0819 
            
Geographic origin            
Europe 81% 72% 49%         
North Africa 4% 5% 3%         
Sub-Saharan Africa  9% 11% 25% <0.0001        
Other 6% 12% 23%         
            
Smoking environment (yes vs no) 74% 47% 33% <0.0001  4.75 3.02-7.49 <0.0001 1.69 1.01-2.82 0.0463 
            
IV drug addiction as HIV risk factor (yes vs no) 23% 10% 1% <0.0001  24.46 4.75-126.14 0.0001 14.60 2.61-81.48 0.0022 
Disclosure of HIV status (yes vs no)             
Disclosure to family  77% 63% 56% <0.0001  1.81 1.16-2.85 0.0097 1.08 0.66-1.77 0.7622 
Disclosure to friends  80% 70% 55% <0.0001        
Experience of rejection due to disclosure  38% 20% 20% <0.0001  1.90 1.14-3.17 0.0134 1.08 0.59-2.00 0.8051 
Depression* (0-21) mean  SD 5.43.6 5.04.1 4.63.9 0.0921        
Anxiety* (0-21) mean  SD 9.24.0 8.04.2 7.84.4 0.0011        
            
CD4 cell count (/mm3)            
 < 200 12% 15% 9%         
 200-500 41% 46% 53% 0.0583        
> 500 47% 39% 38%         
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 Bivariate analysis Multipartite analysis 
   Active smokers versus  
Non-smokers 
Former smokers  
versus non-smokers 
Variables Active 
smokers
N=254 
Former 
smokers 
N=103 
Non 
smokers 
N=236 
 
 
p 
  
 
OR 
 
 
95% CI 
 
 
p 
 
 
OR 
 
 
95% CI 
 
 
p 
HIV therapy            
Perception of antiretroviral toxicity 74% 78% 64% 0.0287        
Subjective perception of adverse antiretroviral 
effects**  
95% 89% 91% 0.1254        
            
Excessive alcohol consumption (yes vs no)*** 25% 14% 6% <0.0001  2.50 1.20-5.23 0.0145 2.03 0.86-4.76 0.1057 
            
Illicit drug consumption (yes vs no)**** 39% 17% 14% <0.0001  2.43 1.41-4.19 0.0014 1.04 0.53-2.05 0.8996 
            
Social plans (yes versus no)            
Plans to change job 46% 33% 44% 0.1092        
To move house  68% 52% 58% 0.0113        
To have children  18% 17% 26% 0.0867        
To practice sports  68% 75% 61% 0.0415  0.90 0.57-1.42 0.6621 1.81 1.07-3.08 0.0282 
To take part in a cultural activity  68% 64% 52% 0.0021        
To make new friends  83% 73% 69% 0.0026        
To take better care of oneself  96% 99% 98% 0.1639        
 
Note:  
* Hospital Anxiety and Depression (HAD) scale 
** Experience of at least one of a predefined list of symptoms during the previous 4 weeks 
*** Defined as DETA-CAGE above 2 
**** At least one illicit substance consumptium (excepte cannabis) during the previous 6 months. 
OR: Odds ratio; CI 95% confidence interval  
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Table 3: Bivariate and multivariate analyses of factors associated with dependence on tobacco in the 210 out of the 254 HIV-infected active smokers 
for whom the Fagerström test was assessable. 
  
Variables Bivariate analysis Multivariate analysis 
 Tobacco Dependency p OR 95% CI  p 
 Strong or moderate
(Fagerström test ≥5)
Mild or none 
(Fagerström test <5) 
     
 N= 119 (57%) N=91 (43%)      
        
Body surface area (m2) mean  SD 1.780.18 1.820.19 0.1190     
HIV risk factor        
IV drug addiction 31% 18%      
Homosexuality 34% 51% 0.0376     
Other 35% 31%      
            
Disclosure of HIV status         
Disclosure to family  (yes vs no) 86% 67% 0.0022 2.04 1.04-3.77  0.0308 
Number of individuals aware of HIV status > 5 74% 62% 0.1629     
            
Depression * (0-21) mean  SD 5.93.8 4.94.4 0.0671     
            
HIV therapy toxicity        
Perception of antiretroviral toxicity (yes vs no) 59% 93% 0.1199     
Negative side effects** 98% 92% 0.0802     
        
Social activities or plans        
To practice sport  43% 63% 0.0069 0.45 0.25-0.79  0.0062 
To have children  17% 10% 0.1870     
To take part in a cultural activity 65% 77% 0.0778     
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Variables Bivariate analysis Multivariate analysis 
 Tobacco Dependency p OR 95% CI  p 
 Strong or moderate
(Fagerström test ≥5)
Mild or none 
(Fagerström test <5) 
     
To travel 82% 89% 0.1484     
To take better care of oneself 95% 99% 0.1139     
        
Other addictions        
Anti-anxiety, sleeping pills 39% 18% 0.0012     
Morning alcohol consumption to feel good 8% 0% 0.0189     
Heroin consumption during one’s life 42% 28% 0.0514     
Substitute drugs, morphine consumption during one’s life 31% 17% 0.0473     
Substitute drugs, morphine consumption during the 
previous 6 months 
23% 7% 0.0056 3.33 1.22-9.60  0.0227 
 
Note:  
Dependence assessed through Fagerström test  
* Hospital Anxiety and Depression (HAD) scale 
**  Experience of at least one of a predefined list of symptoms during the previous 4 weeks 
OR: Odds ratio; CI 95% confidence interval 
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Figures’ legends: 
 
 
Figure 1: Dendrogram showing the results of Ward's cluster analysis : hierarchical relationships 
among dependencies in the study population. 
 
Figure 1 note: 
Results are expressed by name of substance consumed, % of consumers among the study 
population (n=593), and among the smokers (n=254); LSD: lysergic acid diethylamide. The 
semi-partial R-square is an indicator of cluster isolation : high semi-partial r-square values 
indicate a high level of cluster independence. 
 
 
 
 
 
